Grant: Collaborative Health Research Projects
University of Toronto
$212,040.00
Neonatal Stem Cell Secretomes as a Novel Regenerative Therapy for Heart Failure
FY 2020-21
Summary
Heart failure has a universally poor outcome, with only 50% of patients surviving a further five years after diagnosis. The medications that are available for heart failure have little impact onpatient survival, mostly targeting the control of disease symptoms. Regenerative medicine, where the heart is promoted to repair itself, is a new, potentially disruptive, treatment
paradigm that could provide lasting change to organ function. In determining how this concept could be harnessed for benefit, we and others have described how the hearts of very young patients (neonates) have a higher intrinsic ability to repair and regenerative themselves. Using tissue samples from pediatric patients undergoing open heart surgery, we have found
that cells with regenerative potential (stem cells) isolated from neonatal hearts secrete different molecules than cells isolated from older patients. We now propose to harness this capacity into a novel biologic therapy for heart failure patients.
We have collected and preliminarily characterized an initial set of samples from pediatric heart surgery patients. In this project, we will expand our analysis to include a broader range of patient age and cardiac diagnosis. The secreted mixtures will be tested for regenerative potential in established assays, and their composition determined, illuminating the components with the highest therapeutic potential. Using a novel biocompatible scaffold invented by a member of our collaborative group, we will create an optimal delivery vehicle for injection into the failing hearts of patients, allowing for sustained release of the reparative molecules. Finally, we will test the utility of the new therapies in a large animal model of heart failure. We will work in close collaboration with our industry partner, Bluerock Therapeutics, whose sole mandate is to bring regenerative therapies to market, allowing for immediate commercial application and translation into patient care.
Program
Collaborative Health Research Projects
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
538821-2019
Name nom
Maynes, Jason
Department département
Biochemistry (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2019
Award amount
212040
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Installment
inst:2 - 3
Partie
2
Nb partie
3
Application title
Neonatal Stem Cell Secretomes as a Novel Regenerative Therapy for Heart Failure
Keyword
NSERC
Application summary
Heart failure has a universally poor outcome, with only 50% of patients surviving a further five years after diagnosis. The medications that are available for heart failure have little impact onpatient survival, mostly targeting the control of disease symptoms. Regenerative medicine, where the heart is promoted to repair itself, is a new, potentially disruptive, treatment
paradigm that could provide lasting change to organ function. In determining how this concept could be harnessed for benefit, we and others have described how the hearts of very young patients (neonates) have a higher intrinsic ability to repair and regenerative themselves. Using tissue samples from pediatric patients undergoing open heart surgery, we have found
that cells with regenerative potential (stem cells) isolated from neonatal hearts secrete different molecules than cells isolated from older patients. We now propose to harness this capacity into a novel biologic therapy for heart failure patients.
We have collected and preliminarily characterized an initial set of samples from pediatric heart surgery patients. In this project, we will expand our analysis to include a broader range of patient age and cardiac diagnosis. The secreted mixtures will be tested for regenerative potential in established assays, and their composition determined, illuminating the components with the highest therapeutic potential. Using a novel biocompatible scaffold invented by a member of our collaborative group, we will create an optimal delivery vehicle for injection into the failing hearts of patients, allowing for sustained release of the reparative molecules. Finally, we will test the utility of the new therapies in a large animal model of heart failure. We will work in close collaboration with our industry partner, Bluerock Therapeutics, whose sole mandate is to bring regenerative therapies to market, allowing for immediate commercial application and translation into patient care.